WO2007046811A3 - Diagnostic markers of stroke and cerebral injury and methods of use thereof - Google Patents

Diagnostic markers of stroke and cerebral injury and methods of use thereof Download PDF

Info

Publication number
WO2007046811A3
WO2007046811A3 PCT/US2005/038225 US2005038225W WO2007046811A3 WO 2007046811 A3 WO2007046811 A3 WO 2007046811A3 US 2005038225 W US2005038225 W US 2005038225W WO 2007046811 A3 WO2007046811 A3 WO 2007046811A3
Authority
WO
WIPO (PCT)
Prior art keywords
stroke
methods
diagnosis
evaluation
transient ischemic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/038225
Other languages
French (fr)
Other versions
WO2007046811A2 (en
Inventor
Gunars E Valkirs
Jeffrey R Dahlen
Howard J Kirchick
Kenneth F Buechler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alere San Diego Inc
Original Assignee
Biosite Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosite Inc filed Critical Biosite Inc
Priority to PCT/US2005/038225 priority Critical patent/WO2007046811A2/en
Priority to EP05846524A priority patent/EP1949103A2/en
Publication of WO2007046811A2 publication Critical patent/WO2007046811A2/en
Anticipated expiration legal-status Critical
Publication of WO2007046811A3 publication Critical patent/WO2007046811A3/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to methods for the diagnosis and evaluation of stroke and transient ischemic attacks. A variety of markers are disclosed for assembling a panel for such diagnosis and evaluation. In various aspects, the invention provides methods for early detection and differentiation of stroke types and transient ischemic attacks, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for cerebral vasospasm. Invention methods provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.
PCT/US2005/038225 2005-10-20 2005-10-20 Diagnostic markers of stroke and cerebral injury and methods of use thereof Ceased WO2007046811A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/US2005/038225 WO2007046811A2 (en) 2005-10-20 2005-10-20 Diagnostic markers of stroke and cerebral injury and methods of use thereof
EP05846524A EP1949103A2 (en) 2005-10-20 2005-10-20 Diagnostic markers of stroke and cerebral injury and methods of use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/038225 WO2007046811A2 (en) 2005-10-20 2005-10-20 Diagnostic markers of stroke and cerebral injury and methods of use thereof

Publications (2)

Publication Number Publication Date
WO2007046811A2 WO2007046811A2 (en) 2007-04-26
WO2007046811A3 true WO2007046811A3 (en) 2009-04-02

Family

ID=37962925

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/038225 Ceased WO2007046811A2 (en) 2005-10-20 2005-10-20 Diagnostic markers of stroke and cerebral injury and methods of use thereof

Country Status (2)

Country Link
EP (1) EP1949103A2 (en)
WO (1) WO2007046811A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
EP3336551B1 (en) 2008-08-11 2023-05-31 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
US12601749B2 (en) 2008-08-11 2026-04-14 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
AU2010291933B2 (en) 2009-09-14 2016-09-08 Banyan Biomarkers, Inc. Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
JP2020500508A (en) 2016-10-28 2020-01-16 バンヤン・バイオマーカーズ・インコーポレーテッド Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
GB2563415A (en) * 2017-06-14 2018-12-19 Randox Laboratories Ltd Combinations for use in stroke diagnosis
US20200147125A1 (en) * 2017-07-31 2020-05-14 Fadi Basil NAHAB Detection of high risk arterial thromboembolic diseases by markers of coagulation and hemostatic activation

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BARBER ET AL: "Hemostatic function and progressing ischemic stroke: D-dimer predicts early clinical progression.", STROKE, vol. 35, 2004, pages 1421 - 1425 *
CEOROLI ET AL: "Nitric Oxide production and perivascular tyrosine nitration following focal ischemia in neonatal rat.", J. NEUROCHEMISTRY, vol. 70, 1998, pages 2516 - 2525 *
CLARK ET AL: "et al. Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia.", NEUROSCIENCE LETTERS, vol. 238, 1997, pages 53 - 56 *
EIKELBOOM ET AL: "C-reactive protein in ischemic stroke and its etiologic subtypes.", JOURNAL OF STROKE AND CEREBROVASCULAR DISEASES, vol. 12, 2003, pages 74 - 81 *
HATFIELD ET AL: "CSF neuron-specific enolase as a quantitative marker of neuronal damage in a rat stroke model.", BRAIN RESEARCH, vol. 577, 17 April 1992 (1992-04-17) *
MAET ET AL: "RAGE is expressed in pyramidal cells of the hippocampus following moderate hypoxic-ischemic brain injury in rats.", BRAIN RESEARCH., vol. 966, 2003, pages 167 - 174 *
SHIRASAKI ET AL: "Serum s-100b protein as a biomarker for the assessment ofneuroprotectants.", BRAIN RESEARCH., vol. 1021, 2004, pages 159 - 166 *
ZHUO ET AL: "HBO suppresses Nogo-A, NgR, or RhoA expresion in the cerebral cortex after global ischemia.", BBRC., vol. 309, 2003, pages 368 - 376 *

Also Published As

Publication number Publication date
WO2007046811A2 (en) 2007-04-26
EP1949103A2 (en) 2008-07-30

Similar Documents

Publication Publication Date Title
WO2006036220A3 (en) Cellular fibronectin as a diagnostic marker in stroke and methods of use thereof
DE60233949D1 (en) DIAGNOSTIC MARKERS FOR STROKE AND HARNTRAUMA AND METHOD OF USE THEREOF
BRPI0507442A (en) methods of diagnosis and treatment of preeclampsia or eclampsia
WO2005114190A3 (en) Methods of identifying biomarkers
WO2006073682A3 (en) Diagnostic test
WO2007136617A3 (en) Endothelial-monocyte activating polypeptide ii, a biomarker for use in diagnosis of brain injury
WO2008108803A3 (en) Immune cell biosensors and methods of using same
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2008122670A3 (en) Human diabetes susceptibility tnfrsf10b gene
WO2004020968A3 (en) Mutations in nod2 are associated with fibrostenosing disease in patients with crohn’s disease
EP3498729A3 (en) Therapeutic targets for alzheimer's disease
EP4273548A3 (en) Serologic assay for silent brain ischemia
WO2007109571A3 (en) Methods of predicting and monitoring tyrosine kinase inhibitor therapy
WO2006085984A3 (en) Immune cell biosensors and methods of using same
WO2013022953A3 (en) Biomarker for alzheimer's disease and/or mild cognitively impairment, and use thereof
WO2011064225A8 (en) Novel diagnostic method for the diagnosis of alzheimer's disease or mild cognitive impairment
WO2012018535A3 (en) Wellness panel
WO2006084195A3 (en) Personal assessment including familial risk analysis for personalized disease prevention plan
WO2006076025A3 (en) Immune cell biosensors and methods of using same
EP2527466A3 (en) Genetic variants on CHR2 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2006055524A3 (en) Biomarkers for diagnosing schizophrenia and bipolar disorder
WO2008019052A3 (en) Methods and compositions for identifying biomarkers
EP4235181A3 (en) Biomarker detection process and assay of neurological condition
WO2010105235A3 (en) Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy
WO2007080597A3 (en) Polynucleotide and polypeptide sequences and methods for diagnosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005846524

Country of ref document: EP